Objective,2,To evaluate the clinical efficacy of Dr. Yu’s integrated Chinese and Western medicine classification and treatment protocol for polycystic ovary syndrome （PCOS）.,Methods,2,A total of 130 patients with PCOS were randomly divided into a treatment group （,n,=65） and a control group （,n,=65）. The treatment group was treated with the integrated Chinese and Western medicine classification and treatment protocol first proposed by Dr. Yu Jin （i.e.， patients were first classified into 4 types： PCOS Ia， PCOS Ib， PCOS Ⅱa and PCOS Ⅱb， and then given Kuntai Prescription together with ethinyl estradiol （EE） or dexamethasone or metformin according to patients’ condition）， while the control group was treated with the recommended western medicine based on the conventional treatment scheme. The duration of treatment was 6 months in both groups. The clinical efficacy， ovulation rate， pregnancy rate and medication safety were observed， and the reproductive endocrine-related indexes ［follicle-stimulating hormone （FSH）， luteinizing hormone （LH）， estradiol （E,2,）， testosterone （T）， dehydroepiandrosterone sulfate （DHEA-S）， sex hormone-binding globulin （SHBG）， cortisol （C）， 17α-hydroxyprogesterone （17α-OHP）］， glucose metabolism indexes ［fasting plasma glucose （FPG）， fasting insulin （FINS）， homeostatic model assessment for insulin resistance （HOMA-IR）］， body mass index （BMI）， waist-to-hip ratio （WHR） before and after treatment were compared. The ovulation rate and pregnancy rate were observed during 6 months follow-up after treatment.,Results,2,①There were 122 cases who finally completed the trial， 60 cases in the treatment group and 62 cases in the control group. ②Among them， 2 cases （3.3%） had PCOS Ia， 19 cases （31.7%） had PCOS Ib， 34 cases （56.7%） had PCOS Ⅱa， and 5 cases （8.3%） had PCOS Ⅱb. ③The total effective rate was 91.7% in the treatment group and 82.3% in the control group. The difference in the clinical efficacy between the two groups was statistically significant， and the treatment group showed better clinical efficacy than that of the control group （,P,<,0.05）. ④The intra-group comparison showed that BMI， WHR， FINS and HOMA-IR were lowered after treatment in both groups， and the difference was statistically significant （,P,<,0.05）. The inter-group comparison showed that there was no significant difference in BMI， WHR， FINS， and HOMA-IR between the two groups after treatment （,P,>,0.05）. ⑤The intra-group comparison showed that LH and T levels were significantly lowered in both groups after treatment （,P,<,0.05）， and SHBG levels significantly increased in the treatment group after treatment （,P,<,0.05） while the difference in SHBG levels in the control group was not significant before and after treatment （,P,>,0.05）. According to the inter-group comparison after treatment， the differences in levels of FSH， E,2,， DHEA-S， C and 17α-OHP between the two groups were not statistically significant （,P,>,0.05）， but the differences in SHBG and T levels were statistically significant， with the improvement in the treatment group being better than that in the control group （,P,<,0.05）， while the difference in LH levels was statistically significant， with the improvement in the control group being better than that in the treatment group （,P,<,0.05）. ⑥The inter-group comparison showed that the ovulation rate and pregnancy rate were significantly higher in the treatment group than those in the control group （,P,<,0.05）. ⑦There were no serious adverse events related to medication administration that required discontinuation during the treatment course in the two groups.,Conclusion,2,Compared with the single use of conventional Western medicine， Dr. Yu’s integrated Chinese and Western medicine classification and treatment protocol for PCOS has shown better clinical efficacy， which can improve the overall reproductive endocrine and glucose metabolism disorders of the human body to promote the ovulation rate and pregnancy rate.